FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2592409589> ?p ?o ?g. }

• W2592409589 abstract "Abstract Abstract 4356 Background: Platelet inhibition by clopidogrel is highly variable. Patients with reduced inhibition have increased risk for major adverse cardiovascular events. The aim of this study was to determine whether known genetic, drug, dietary, compliance and lifestyle factors affecting clopidogrel absorption and metabolism fully account for the variability in clopidogrel pharmacokinetics and pharmacodynamics. Methods and Results: Healthy subjects (n=160; age 20–53; homozygous CYP2C19 extensive metabolizer genotype; no nicotine 6 weeks, prescription drugs 4 weeks, over-the-counter drugs 2 weeks, caffeine and alcohol 72 hours; confined; restricted diet) received clopidogrel 75 mg daily for 9 days. At steady-state, clopidogrel active metabolite (clopidogrelAM) pharmacokinetics varied widely between subjects (CVs 33.8% and 40.2% for clopidogrelAM AUCt and Cmax, respectively). On-treatment pharmacodynamic endpoints VASP P2Y12 platelet reactivity index (PRI), maximal platelet aggregation (MPA) to ADP, and VerifyNow P2Y12 platelet response units (PRU) also varied widely (CVs 32 – 53%). All identified factors together accounted for only 18% of inter-subject variation in pharmacokinetic parameters and 32 – 64% of inter-subject variation in PRI, MPA, and PRU. High on-treatment platelet reactivity was present in 45% of healthy, homozygous CYP2C19 extensive metabolizer subjects, free of nicotine, alcohol, and co-medications, with witnessed clopidogrel 75 mg/d treatment for 9 days. Conclusions: Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite rigorous exclusion or control of known disease, polymorphisms (CYP2C19, CYP3A5, ABCB1, PON1), non-compliance, co-medications, diet, smoking, alcohol, demographics, and pre-treatment platelet hyperreactivity. Thus, as yet unidentified factors contribute to high on-treatment platelet reactivity with its known increased risk of major adverse cardiovascular events. Disclosures: Frelinger: Takeda Pharmaceuticals: Research Funding; GLSynthesis: Research Funding. Bhatt:Medscape Cardiology: Membership on an entity's Board of Directors or advisory committees; Boston VA Research Institute: Membership on an entity's Board of Directors or advisory committees; Society of Chest Pain Centers: Membership on an entity's Board of Directors or advisory committees; American Heart Association Get With The Guidelines Science Subcommittee: Chair, Chair Other; American College of Cardiology: Editor, Clinical Trials, Cardiosource Other; Duke Clinical Research Institute: clinical trial steering committees, clinical trial steering committees Other; Slack Publications: Chief Medical Editor, Cardiology Today Intervention Other; WebMD: CME steering committees, CME steering committees Other; Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi Aventis, The Medicines Company: Research Funding; PLx Pharma, Takeda: unfunded research Other. Lee:Takeda Global Research & Development Center, Inc: Employment. Mulford:Takeda Global Research & Development Center, Inc: Employment. Wu:Takeda Global Research & Development Center, Inc: Employment. Nudurupati:Takeda Global Research & Development Center, Inc: Employment. Michelson:Eli Lilly: Data monitoring committee and idependent external monitor of clinical trials, Research Funding; Takeda: Research Funding; Oxygen Biotherapeutics: Research Funding; Alexion: Research Funding; Omthera: Research Funding." @default.
• W2592409589 created "2017-03-16" @default.
• W2592409589 creator A5007811084 @default.
• W2592409589 creator A5010571732 @default.
• W2592409589 creator A5016792003 @default.
• W2592409589 creator A5045474774 @default.
• W2592409589 creator A5049621478 @default.
• W2592409589 creator A5049630475 @default.
• W2592409589 creator A5056663369 @default.
• W2592409589 creator A5059897060 @default.
• W2592409589 creator A5061071610 @default.
• W2592409589 creator A5067192657 @default.
• W2592409589 creator A5073552243 @default.
• W2592409589 date "2012-11-16" @default.
• W2592409589 modified "2023-09-29" @default.
• W2592409589 title "Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Non-Compliance, Diet, Smoking, Co-Medications (including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet Function" @default.
• W2592409589 doi "https://doi.org/10.1182/blood.v120.21.4356.4356" @default.
• W2592409589 hasPublicationYear "2012" @default.
• W2592409589 type Work @default.
• W2592409589 sameAs 2592409589 @default.
• W2592409589 citedByCount "1" @default.
• W2592409589 countsByYear W25924095892013 @default.
• W2592409589 crossrefType "journal-article" @default.
• W2592409589 hasAuthorship W2592409589A5007811084 @default.
• W2592409589 hasAuthorship W2592409589A5010571732 @default.
• W2592409589 hasAuthorship W2592409589A5016792003 @default.
• W2592409589 hasAuthorship W2592409589A5045474774 @default.
• W2592409589 hasAuthorship W2592409589A5049621478 @default.
• W2592409589 hasAuthorship W2592409589A5049630475 @default.
• W2592409589 hasAuthorship W2592409589A5056663369 @default.
• W2592409589 hasAuthorship W2592409589A5059897060 @default.
• W2592409589 hasAuthorship W2592409589A5061071610 @default.
• W2592409589 hasAuthorship W2592409589A5067192657 @default.
• W2592409589 hasAuthorship W2592409589A5073552243 @default.
• W2592409589 hasConcept C111113717 @default.
• W2592409589 hasConcept C112705442 @default.
• W2592409589 hasConcept C126322002 @default.
• W2592409589 hasConcept C140840227 @default.
• W2592409589 hasConcept C22979827 @default.
• W2592409589 hasConcept C2777628954 @default.
• W2592409589 hasConcept C2777849778 @default.
• W2592409589 hasConcept C2909112448 @default.
• W2592409589 hasConcept C49059817 @default.
• W2592409589 hasConcept C526171541 @default.
• W2592409589 hasConcept C62231903 @default.
• W2592409589 hasConcept C71924100 @default.
• W2592409589 hasConcept C89560881 @default.
• W2592409589 hasConcept C98274493 @default.
• W2592409589 hasConceptScore W2592409589C111113717 @default.
• W2592409589 hasConceptScore W2592409589C112705442 @default.
• W2592409589 hasConceptScore W2592409589C126322002 @default.
• W2592409589 hasConceptScore W2592409589C140840227 @default.
• W2592409589 hasConceptScore W2592409589C22979827 @default.
• W2592409589 hasConceptScore W2592409589C2777628954 @default.
• W2592409589 hasConceptScore W2592409589C2777849778 @default.
• W2592409589 hasConceptScore W2592409589C2909112448 @default.
• W2592409589 hasConceptScore W2592409589C49059817 @default.
• W2592409589 hasConceptScore W2592409589C526171541 @default.
• W2592409589 hasConceptScore W2592409589C62231903 @default.
• W2592409589 hasConceptScore W2592409589C71924100 @default.
• W2592409589 hasConceptScore W2592409589C89560881 @default.
• W2592409589 hasConceptScore W2592409589C98274493 @default.
• W2592409589 hasLocation W25924095891 @default.
• W2592409589 hasOpenAccess W2592409589 @default.
• W2592409589 hasPrimaryLocation W25924095891 @default.
• W2592409589 hasRelatedWork W1602687237 @default.
• W2592409589 hasRelatedWork W2016921425 @default.
• W2592409589 hasRelatedWork W2227382611 @default.
• W2592409589 hasRelatedWork W2312118733 @default.
• W2592409589 hasRelatedWork W2563749973 @default.
• W2592409589 hasRelatedWork W2994157735 @default.
• W2592409589 hasRelatedWork W3095281544 @default.
• W2592409589 hasRelatedWork W3096456327 @default.
• W2592409589 hasRelatedWork W3096630386 @default.
• W2592409589 hasRelatedWork W3189211235 @default.
• W2592409589 hasRelatedWork W3214004110 @default.
• W2592409589 hasRelatedWork W4916723 @default.
• W2592409589 isParatext "false" @default.
• W2592409589 isRetracted "false" @default.
• W2592409589 magId "2592409589" @default.
• W2592409589 workType "article" @default.